206 related articles for article (PubMed ID: 24462666)
1. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases.
Johannes JW; Chuaqui C; Cowen S; Devereaux E; Gingipalli L; Molina A; Wang T; Whitston D; Wu X; Zhang HJ; Zinda M
Bioorg Med Chem Lett; 2014 Feb; 24(4):1138-43. PubMed ID: 24462666
[TBL] [Abstract][Full Text] [Related]
2. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.
Wang T; Block MA; Cowen S; Davies AM; Devereaux E; Gingipalli L; Johannes J; Larsen NA; Su Q; Tucker JA; Whitston D; Wu J; Zhang HJ; Zinda M; Chuaqui C
Bioorg Med Chem Lett; 2012 Mar; 22(5):2063-9. PubMed ID: 22305584
[TBL] [Abstract][Full Text] [Related]
3. 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.
Bamborough P; Christopher JA; Cutler GJ; Dickson MC; Mellor GW; Morey JV; Patel CB; Shewchuk LM
Bioorg Med Chem Lett; 2006 Dec; 16(24):6236-40. PubMed ID: 16997559
[TBL] [Abstract][Full Text] [Related]
4. Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
Lefranc J; Schulze VK; Hillig RC; Briem H; Prinz F; Mengel A; Heinrich T; Balint J; Rengachari S; Irlbacher H; Stöckigt D; Bömer U; Bader B; Gradl SN; Nising CF; von Nussbaum F; Mumberg D; Panne D; Wengner AM
J Med Chem; 2020 Jan; 63(2):601-612. PubMed ID: 31859507
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta).
Christopher JA; Bamborough P; Alder C; Campbell A; Cutler GJ; Down K; Hamadi AM; Jolly AM; Kerns JK; Lucas FS; Mellor GW; Miller DD; Morse MA; Pancholi KD; Rumsey W; Solanke YE; Williamson R
J Med Chem; 2009 May; 52(9):3098-102. PubMed ID: 19348415
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKε for the treatment of obesity.
Beyett TS; Gan X; Reilly SM; Gomez AV; Chang L; Tesmer JJG; Saltiel AR; Showalter HD
Bioorg Med Chem; 2018 Nov; 26(20):5443-5461. PubMed ID: 30270002
[TBL] [Abstract][Full Text] [Related]
8. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Stavenger RA; Cui H; Dowdell SE; Franz RG; Gaitanopoulos DE; Goodman KB; Hilfiker MA; Ivy RL; Leber JD; Marino JP; Oh HJ; Viet AQ; Xu W; Ye G; Zhang D; Zhao Y; Jolivette LJ; Head MS; Semus SF; Elkins PA; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Doe CP; Bentley R; Chen ZX; Hu E; Lee D
J Med Chem; 2007 Jan; 50(1):2-5. PubMed ID: 17201404
[TBL] [Abstract][Full Text] [Related]
9. 2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
Zhong M; Bui M; Shen W; Baskaran S; Allen DA; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris SO; Heumann SA; Hoch U; Ivy SN; Jacobs JW; Lam S; Lee H; McDowell RS; Oslob JD; Purkey HE; Romanowski MJ; Silverman JA; Tangonan BT; Taverna P; Yang W; Yoburn JC; Yu CH; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2009 Sep; 19(17):5158-61. PubMed ID: 19646866
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in regulation of IFN-inducible genes.
Ikeda F; Hecker CM; Rozenknop A; Nordmeier RD; Rogov V; Hofmann K; Akira S; Dötsch V; Dikic I
EMBO J; 2007 Jul; 26(14):3451-62. PubMed ID: 17599067
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
[TBL] [Abstract][Full Text] [Related]
13. 3,5-Disubstituted-indole-7-carboxamides: the discovery of a novel series of potent, selective inhibitors of IKK-β.
Miller DD; Bamborough P; Christopher JA; Baldwin IR; Champigny AC; Cutler GJ; Kerns JK; Longstaff T; Mellor GW; Morey JV; Morse MA; Nie H; Rumsey WL; Taggart JJ
Bioorg Med Chem Lett; 2011 Apr; 21(8):2255-8. PubMed ID: 21429745
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases.
McIver EG; Bryans J; Birchall K; Chugh J; Drake T; Lewis SJ; Osborne J; Smiljanic-Hurley E; Tsang W; Kamal A; Levy A; Newman M; Taylor D; Arthur JS; Clark K; Cohen P
Bioorg Med Chem Lett; 2012 Dec; 22(23):7169-73. PubMed ID: 23099093
[TBL] [Abstract][Full Text] [Related]
16. Identification and further development of potent TBK1 inhibitors.
Richters A; Basu D; Engel J; Ercanoglu MS; Balke-Want H; Tesch R; Thomas RK; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):289-98. PubMed ID: 25540906
[TBL] [Abstract][Full Text] [Related]
17. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
[TBL] [Abstract][Full Text] [Related]
18. Discovery of piperidinyl aminopyrimidine derivatives as IKK-2 inhibitors.
Kim S; Jung JK; Lee HS; Kim Y; Kim J; Choi K; Baek DJ; Moon B; Oh KS; Lee BH; Shin KJ; Pae AN; Nam G; Roh EJ; Cho YS; Choo H
Bioorg Med Chem Lett; 2011 May; 21(10):3002-6. PubMed ID: 21489792
[TBL] [Abstract][Full Text] [Related]
19. The discovery of thienopyridine analogues as potent IkappaB kinase beta inhibitors. Part II.
Wu JP; Fleck R; Brickwood J; Capolino A; Catron K; Chen Z; Cywin C; Emeigh J; Foerst M; Ginn J; Hrapchak M; Hickey E; Hao MH; Kashem M; Li J; Liu W; Morwick T; Nelson R; Marshall D; Martin L; Nemoto P; Potocki I; Liuzzi M; Peet GW; Scouten E; Stefany D; Turner M; Weldon S; Zimmitti C; Spero D; Kelly TA
Bioorg Med Chem Lett; 2009 Oct; 19(19):5547-51. PubMed ID: 19716697
[TBL] [Abstract][Full Text] [Related]
20. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
